open access

Vol 6, No 4 (2021)
Letter to the Editor
Published online: 2021-11-02
Get Citation

COVID-19 vaccine — third dose, booster dose? What is it and is it necessary?

Anatolyi Gozhenko1, Lukasz Szarpak234, Milosz J. Jaguszewski5, Beata Dey2, Julia Popieluch2, Michal Pruc3, Gabriela Borkowska6, Krzysztof J. Filipiak2
·
Disaster Emerg Med J 2021;6(4):208-209.
Affiliations
  1. International European University, Kiev, Ukraine
  2. Institute of Outcomes Research, Maria Sklodowska-Curie Medical Academy, Warsaw, Poland
  3. Research Unit, Polish Society of Disaster Medicine, Warsaw, Poland
  4. Research Unit, Maria Sklodowska-Curie Bialystok Oncology Center, Bialystok, Poland
  5. First Department of Cardiology, Medical University of Gdansk, Poland
  6. Faculty of Medicine, Collegium Medicum, Cardinal Stefan Wyszynski University, Warsaw, Poland

open access

Vol 6, No 4 (2021)
LETTERS TO THE EDITOR
Published online: 2021-11-02

Abstract

Not available

Abstract

Not available
Get Citation

Keywords

SARS-CoV-2, COVID-19, vaccine, epidemiology, outcome

About this article
Title

COVID-19 vaccine — third dose, booster dose? What is it and is it necessary?

Journal

Disaster and Emergency Medicine Journal

Issue

Vol 6, No 4 (2021)

Article type

Letter to the Editor

Pages

208-209

Published online

2021-11-02

Page views

6095

Article views/downloads

649

DOI

10.5603/DEMJ.a2021.0027

Bibliographic record

Disaster Emerg Med J 2021;6(4):208-209.

Keywords

SARS-CoV-2
COVID-19
vaccine
epidemiology
outcome

Authors

Anatolyi Gozhenko
Lukasz Szarpak
Milosz J. Jaguszewski
Beata Dey
Julia Popieluch
Michal Pruc
Gabriela Borkowska
Krzysztof J. Filipiak

References (8)
  1. Boyarsky BJ, Werbel WA, Avery RK, et al. Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients. JAMA. 2021; 325(21): 2204–2206.
  2. Tenforde MW, Patel MM, Ginde AA, et al. Influenza and Other Viruses in the Acutely Ill (IVY) Network. Effectiveness of SARS-CoV-2 mRNA Vaccines for Preventing Covid-19 Hospitalizations in the United States. Clin Infect Dis. 2021 [Epub ahead of print].
  3. Brosh-Nissimov T, Orenbuch-Harroch E, Chowers M, et al. BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel. Clin Microbiol Infect. 2021 [Epub ahead of print].
  4. Chodick G, Tene L, Rotem RS, et al. The effectiveness of the TWO-DOSE BNT162b2 vaccine: analysis of real-world data. Clin Infect Dis. 2021 [Epub ahead of print].
  5. Khan N, Mahmud N. Effectiveness of SARS-CoV-2 Vaccination in a Veterans Affairs Cohort of Patients With Inflammatory Bowel Disease With Diverse Exposure to Immunosuppressive Medications. Gastroenterology. 2021; 161(3): 827–836.
  6. Chemaitelly H, AlMukdad S, Joy J, et al. SARS-CoV-2 vaccine effectiveness in immunosuppressed kidney transplant recipients. .
  7. Ferenci T, Sarkadi B. Virus neutralizing antibody responses after two doses of BBIBP-CorV (Sinopharm, Beijing CNBG) vaccine. .
  8. Tartof S, Slezak J, Fischer H, et al. Six-Month Effectiveness of BNT162B2 mRNA COVID-19 Vaccine in a Large US Integrated Health System: A Retrospective Cohort Study. SSRN Electronic Journal. .

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl